Dr. Kamran Firoozi M.D.

Recommended Articles

• Study Concludes At-home Antibiotic Therapy for Cystic Fibrosis No Riskier than at Hospital

  Many patients would generally perform to have their treatments done at home than in a hospital; it's a familiar place, the patient can be more comfortable, travel isn’t necessary. It was assumed, however, that intravenous antibiotic treatment for cystic fibrosis patients would not be as safe at...

• Everything About the Mycoplasma pneumoniae Infection

  Mycoplasma pneumoniae is a bacterium that causes an infectious respiratory infection. Mycoplasma pneumoniae can spread very easily from person to person via airborne droplets.Lung infections caused by M. pneumoniae can become very serious affecting your heart and nervous system if left...

• Does Cystic Fibrosis Run in the Family?

  Cystic fibrosis is a disease affecting many people throughout the United States and the world. Yet, there is so much information out there that it is sometimes difficult to ascertain the most important facts. With this disease, you may have many lingering questions. How does someone get cystic...

• Staying Healthy as an Adult Living with Cystic Fibrosis

  Cystic fibrosis is a lifelong condition that begins at birth and slowly progresses throughout a person’s life. It is among the most difficult chronic illnesses to treat, manage, and survive. Despite this, the field of cystic fibrosis has made leaps and strides in the last fifty years, more than...

• Can Pleurisy Destroy My Lungs?

  What is pleurisy?Pleurisy is the inflammation of the thin pleural membranes that line the lungs.What happens in pleurisy?A thin membrane called the pleura lines your lungs. The pleura are double-layered membranes that line your lungs as well as the inner aspect of the chest wall. Between these...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...